Castleark Management LLC Purchases 42,560 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Castleark Management LLC raised its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 25.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 211,370 shares of the biopharmaceutical company's stock after acquiring an additional 42,560 shares during the quarter. Castleark Management LLC owned approximately 0.14% of TG Therapeutics worth $6,362,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of TGTX. Vanguard Group Inc. increased its stake in TG Therapeutics by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock valued at $469,454,000 after buying an additional 209,190 shares during the period. Soleus Capital Management L.P. increased its stake in TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock valued at $80,705,000 after purchasing an additional 146,702 shares during the last quarter. Clearbridge Investments LLC purchased a new position in TG Therapeutics during the fourth quarter worth approximately $55,237,000. Northern Trust Corp lifted its stake in shares of TG Therapeutics by 8.6% in the 4th quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock valued at $46,141,000 after purchasing an additional 120,785 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of TG Therapeutics by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after acquiring an additional 84,904 shares during the period. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Stock Up 1.0%

Shares of NASDAQ TGTX traded up $0.33 during midday trading on Monday, reaching $34.57. 1,042,767 shares of the company's stock were exchanged, compared to its average volume of 2,989,933. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. TG Therapeutics, Inc. has a 52-week low of $15.16 and a 52-week high of $46.48. The business's fifty day moving average price is $38.13 and its two-hundred day moving average price is $34.32. The stock has a market capitalization of $5.49 billion, a PE ratio of -345.67 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. During the same period in the previous year, the firm posted ($0.07) EPS. TG Therapeutics's revenue for the quarter was up 90.4% on a year-over-year basis. Analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $40.80.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.